No benefit from daratumumab, bortezomib and dexamethasone (D‐Vd) in real‐world patients with functional high‐risk multiple myeloma: A report from the Myeloma and Related Diseases Registry

The data from the Myeloma and Related Diseases Registry that support the findings of this study are available on request and following approval from the corresponding author and the registry. The data are not publicly available due to privacy and ethical restrictions. The data access policy is available at www.mrdr.net.au.